Targeting Triple NK Cell Suppression Mechanisms: A Comprehensive Review of Biomarkers in Pancreatic Cancer Therapy
Preprint
- 13 December 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a poor prognosis. In this review, we focus on the role of the immune system in PDAC, especially the interactions between natural killer (NK) cells, cancer cells, and the tumor microenvironment (TME). These interactions are important for both tumor growth and resistance to treatment. Despite progress in treatment methods, PDAC remains difficult to manage, underscoring the need for new strategies to improve patient out-comes. NK cells are emerging as a potential therapeutic option, but their effectiveness is limited by a suppressive TME, which reduces NK cell activity and their ability to target tumors. Several mechanisms within the PDAC TME contribute to NK cell dysfunction. Key factors include diminished NK cell proliferation, impaired cytotoxicity, and reduced tumor infiltration. To address these challenges, we used a new concept known as the "Triple NK cell biomarker approach." This approach focuses on three critical factors: tumor characteristics, the TME, and NK cell suppression mechanisms. By identifying and targeting biomarkers associated with these components, the approach could help develop personalized strategies to enhance NK cell activity and improve PDAC treatment outcomes. While existing studies have highlighted the potential of NK cells in PDAC therapy, further research is essential to fully understand their role in treatment resistance.Keywords
All Related Versions
This publication has 143 references indexed in Scilit:
- CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent MechanismAdvanced Science, 2022
- NAD+ salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunityHepatology, 2022
- FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitroStrahlentherapie und Onkologie, 2020
- Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic CancerJAMA Oncology, 2019
- Aptamer‐Engineered Natural Killer Cells for Cell‐Specific Adaptive ImmunotherapySmall, 2019
- Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in miceCancer Immunology, Immunotherapy, 2017
- Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functionsCancer Immunology, Immunotherapy, 2017
- Targeting of the P2X7 receptor in pancreatic cancer and stellate cellsInternational Journal of Cancer, 2016
- Hypoxia downregulates the expression of activating receptors involved in NK‐cell‐mediated target cell killing without affecting ADCCEuropean Journal of Immunology, 2013
- Identification and characterization of a tumor infiltrating CD56+/CD16− NK cell subset with specificity for pancreatic and prostate cancer cell linesCancer Immunology, Immunotherapy, 2010